Abstract
Previous studies revealed some comorbidity of Alzheimer’s disease and osteoporosis not only for advanced disease, but also for the incipient conditions cognitive decline and decline of bone mineral density. To detect comorbidity with osteoporosis at a subclinical level, we studied concentrations of biochemical osteoporosis markers in blood plasma of subjects with mild cognitive impairment and mild Alzheimer’s disease compared to subjects with primary osteoporosis and age-matched cognitively normal controls in an explorative approach. Regarding disease-spanning molecular pathology we also studied osteoprotegerin, a decoy receptor of RANKL and TRAIL. Equally increased C-terminal collagen fragments, marking bone catabolism, were seen in osteoporosis and Alzheimer’s disease (+68%) versus controls. Osteocalcin, marking bone remodelling and anabolism, was concomitantly increased in osteoporosis (+63%), as a trend, and significantly in Alzheimer’s disease (+76%). Osteoprotegerin was unchanged between patient groups and controls. 25 (OH) vitamin D plasma levels were low normal and of equal amount in all groups except for the osteoporosis group. These results point to increased bone catabolism and concomitant remodelling/anabolism unrelated to vitamin D state in mild Alzheimer’s disease, but not in mild cognitive impairment. This corroborates previous findings of comorbidity of Alzheimer’s disease with osteoporosis in the early disease course at the level of biochemical blood markers. Regarding osteoprotegerin, previously reported plasma level increases in Alzheimer’s disease were not observed in this study, which does not rule out subtle changes to be detected in larger samples or the possibility that other components of osteoprotegerin pathways are affected in Alzheimer’s disease.
Similar content being viewed by others
References
Cantarella G, Uberti D, Carsana T et al (2003) Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity. Cell Death Differ 10:134–141
Carlsten H (2005) Immune responses and bone loss: the estrogen connection. Immunol Rev 208:194–206
Christgau S, Bitsch-Jensen O, Bjarnason HN, Henriksen EG, Qvist P, Alexandersen P, Henriksen DB (2000) Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505–511
Corallini F, Rimondi E, Secchiero P (2008) TRAIL and osteoprotegerin: a role in endothelial physiopathology. Front Biosci 13:135–147
Emanuele E, Peros E, Scioli GA et al (2004) Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer’s disease. Int J Mol Med 13:849–853
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental-state. Psychiatry Res 12:189–198
Franceschi C, Bonafe M, Valensin S et al (2000) Inflammaging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908:244–254
Härting C, Markowitsch HJ, Neufeld H et al (eds) (2000) WMS-R Wechsler Gedächtnistest—revidierte Fassung. Deutsche Adaption der Wechsler Memory Scale. Verlag Hans Huber, Bern
Hindmarch I, Lehfeld H, Jongh P et al (1998) The Bayer Activities of Daily Living Scale (B-ADL). Dement Geriatr Cogn Disord 9(Suppl 2):20–26
Hofbauer LC, Schoppet M (2007) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490–495
Hofbauer LC, Cepok S, Hemmer B (2004) Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. Acta Neuropathol 107:575–577
Ihl R, Frölich L (1991) Die Reisberg-Skalen. Beltz Verlag, Weinheim
Ihl R, Grass-Kapanke B (2000) Manual—Test zur Früherkennung von Demenzen mit Depressionsabgrenzung. Libri Books on Demand, Hamburg
Johansson C, Skoog I (1996) A population-based study on the association between dementia and hip fractures in 85-year olds. Aging (Milano) 8:189–196
Jono S, Ikari Y, Shioi A et al (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106:1192–1194
Jorm A (1994) A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med 24:145–153
Kahl KG, Greggersen W, Rudolf S et al (2006) Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosomat Med 68:669–674
Kartsogiannis V, Zhou H, Horwood NJ et al (1999) Localisation of RANKL (receptor activator of NFkB ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25:525–534
Kertesz A, Nadkarni N, Davidson W et al (2000) The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia. J Int Neuropsychol Soc 6:460–468
Kiechl S, Werner P, Knoflach M et al (2006) The osteprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 4:801–811
Kipen E, Helme RD, Wark JD et al (1995) Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. J Am Geriatr Soc 43:1088–1091
Kudlacek S, Schneider B, Woloszczuk W et al (2003) Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32:681–686
Leib ES, Lewiecki M, Binkley N, Hamdy RC (2004) Official positions of the international society for clinical densiometry. J Clin Densiometry 7:1–6
Lui LY, Stone K, Cauley JA et al (2003) Bone loss predicts subsequent cognitive decline in older women: the study of osteoporotic fractures. J Am Geriatr Soc 51:38–43
Martin-Villaba A, Herr I, Jeremias I et al (1999) CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 19:3809–3817
McKenna MJ, Freaney R (1998) Secondary hyperparathyroidism in the elderly; means to defining hypovitaminosis D. Osteoporos Int 8(Suppl):S3–S6
McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944
Morris JC (1997) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:2412–2414
Naumann U, Wick W, Beschorner R et al (2004) Expression and functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathol 107:17–22
Ovesen L, Andersen R, Jakobsen J (2003) Geographical differences in vitamin D status, with particular reference to European countries. Proc Nutr Soc 62:813–821
Petersen RC, Smith GE, Waring SC et al (1999) Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 56:303–308
Rachon D, Mysliwska J, Suchecka-Rachon K et al (2002) Effects of oestrogen deprivation on interleukin-6 production by blood mononuclear cells of postmenopausal women. J Endocrinol 172:387–395
Reitan RM (1979) Trail Making Test (TMT). Hogrefe Verlag, Bern
Sato Y, Asoh T, Oizumi K (1998) High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer’s disease. Bone 23:555–557
Schoppet M, Preissner KT, Hofbauer LC (2002) RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 22:549–553
Shulman KI (2000) Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15:548–561
Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319
Tan ZS, Seshadri S, Beiser A et al (2005) Bone mineral density and the risk of Alzheimer disease. Arch Neurol 62:107–111
Thalmann B, Monsch AU, Bernasconi F et al (1998) Die CERAD Neuropsychologische Testbatterie—Ein gemeinsames minimales Instrumentarium zur Demenzabklärung. Memory Clinic, Geriatrische Universitätsklinik, Basel
Uberti D, Cantarella G, Facchetti F et al (2004) TRAIL is expressed in the brain cells of Alzheimer’s disease patients. Neuroreport 15:579–581
Yaffe K, Browner W, Cauley J et al (1999) Association between bone mineral density and cognitive decline in older women. J Am Geriatr Soc 47:1176–1182
Yano K, Tsuda E, Washida N et al (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518–527
Yasuda H, Shima N, Nakagawa N et al (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329–1337
Zhang Y, Seshadri S, Ellison RC et al (2001) Bone mineral density and verbal memory impairment: third National Health and Nutrition Examination Survey. Am J Epidemiol 154:795–802
Acknowledgments
This study was carried out in association with the German Competence Network for Dementias (Kompetenznetz Demenzen), which is supported by the Federal Ministry for Education and Research (Bundesministerium für Bildung und Forschung, grant no. 01GI0420).
Conflict of interest statement
There are no actual or potential conflicts of interest for all authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Luckhaus, C., Mahabadi, B., Grass-Kapanke, B. et al. Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer’s disease. J Neural Transm 116, 905–911 (2009). https://doi.org/10.1007/s00702-009-0241-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-009-0241-x